Skip to content
Menu

ABVC BioPharma, Inc. ABVC

Full chart Compare
Set alert

Price alert · ABVC

All alert types
0.88 USD -0.03 (-3.34%)

Regular-session close

0.90 +0.02 +2.27%

After hours · Nov 19, 4:00 PM ET

0.87 Day range 0.9104
0.707 52-week range 2.89
YTD
-58.69%
1 year
-67.65%

5D -0.1000 (-10.00%)

0.85000.90000.95001.0000ThuFriMonTueWedThu0.9000
Market cap
23.74M
Revenue (ttm)
136.40K
EPS (ttm)
-0.20
Shares out
12.24M
Forward P/E
-1.16
YTD return
-58.69%
1-year return
-67.65%
Volume
57.51K
Avg volume
82.83K
Open
0.9104
Previous close
0.9104
Day's range
0.87 – 0.9104
52-week range
0.707 – 2.89
Beta
0.82

Key statistics

50-day average
0.55548
200-day average
0.8008
Enterprise value
8.67M
Price / sales
45.78
Price / book
0.48
Revenue growth
1817.50%
Free cash flow
-3.19M
Total cash
199.98K
Total debt
2.73M
Return on equity
-320.36%
Short % of float
1.94%

Fundamental scorecard

4 of 25 checks passed on ABVC’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ABVC Revenue — quarterly 0
ABVC Net income — quarterly 1.15M
ABVC EPS — quarterly 0.04

Earnings

ABVC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.02——
Aug 14, 2024Jun 1, 20240.00-0.09——
May 17, 2024Mar 1, 20240.00-0.40——
Mar 13, 2024Dec 1, 20230.00-0.35——
Nov 15, 2023Sep 1, 20230.00-0.82——
Aug 14, 2023Jun 1, 20230.00-0.68——

About ABVC BioPharma, Inc.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on ABVC — it syncs with the Stock Master app.

Institution ownership

ABVC institution ownership
Holder% heldSharesValueReported
Geode Capital Management, LLC0.55%71,60736.52KSep 29, 2024
Vanguard Group Inc0.36%46,94723.94KSep 29, 2024
Avantax Planning Partners, Inc.0.30%39,00019.89KSep 29, 2024
Xtx Topco Ltd0.18%23,40511.94KSep 29, 2024
Northern Trust Corporation0.15%19,1359.76KSep 29, 2024
State Street Corporation0.10%12,9006.58KSep 29, 2024

Fund ownership

ABVC fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.41%52,78326.92KOct 30, 2024
Vanguard Extended Market Index Fund0.36%46,94723.94KSep 29, 2024
Fidelity Total Market Index Fund0.11%14,3877.34KOct 30, 2024
Fidelity Series Total Market Index Fund0.10%12,4616.36KOct 30, 2024